Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134222 | 0.92 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL1066421 | 0.86 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3641576 | 0.84 | HDAC1 (0.73) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3639000 | 0.84 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL4588883 | 0.83 | HDAC1 (0.73) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2209869 | 0.82 | HDAC1 (0.67) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4578962 | 0.82 | HDAC1 (0.79) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3776856 | 0.81 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4506241 | 0.81 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3646210 | 0.81 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010065117-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | HDAC1 2/4885HDAC2 1/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.